Public Health Rehabilition after Acute Myocardial Infarction: a Randomized Controlled Study

Cover Page

Cite item

Full Text

Abstract

Background: Cardiovascular diseases (CVD) are the main causes of death worldwide. The incidence of and mortality from CVD in Kazakhstan is greater than in most neighboring countries warranting urgent public health measures related to both primary, secondary and tertiary prevention. Aims: To assess whether a newly developed 6-months public health rehabilitation program for patients with acute myocardial infarction (AMI) with home visits performed by physician assistants is superior to the standard rehabilitation of these patients in Western Kazakhstan. Methods: A randomized controlled study. A total of 75 AMI patients were enrolled after discharge form the hospital and 72 completed the trial. The control group (n = 34) participated in the standard rehabilitation program while the intervention group (n = 38) underwent and experimental rehabilitation program with home visits in addition to the standard program. Body mass index, waist circumference, blood pressure, heart rate, blood lipids, smoking and compliance to the treatment were assessed at the enrollment and after 6 months of the follow-up. Differences between the changes in the intervention and in the control group were compared using Mann-Whitney tests. Results: The experimental program was superior to the standard program in reducing systolic- (-22.5 vs. -2.9 mm Hg, p < 0.004) and diastolic (-6.3 vs. -0.6 mm Hg, p = 0.032) blood pressure, body mass index (-0.99 vs. 0.53 kg/m2, p < 0.001), waist circumference (-3.0 vs. 1.7 cm, p < 0.001) and the number of smoked cigarettes (-12 vs. -3, p = 0.002). Blood lipid profiles improved in both groups. Although slightly more pronounced changes were observed in the intervention group, the differences did not reach the level of statistical significance. Conclusions: The program was more effective on blood pressure, smoking and obesity-related indicators than the standard rehabilitation. Larger studies are warranted to corroborate our findings prior to implementation of the program in practice.

About the authors

Damira G. Zhamankulova

West Kazakhstan Marat Ospanov Medical University

Email: bianconeri-98@mail.ru
PhD student Aktobe, Kazakhstan

Lazzat M. Zhamaliyeva

West Kazakhstan Marat Ospanov Medical University

Aktobe, Kazakhstan

Gulnara L. Kurmanalina

West Kazakhstan Marat Ospanov Medical University

Aktobe, Kazakhstan

Ziyash Tanbetova

West Kazakhstan Marat Ospanov Medical University

Aktobe, Kazakhstan

Andrey M. Grjibovski

West Kazakhstan Marat Ospanov Medical University; Northern State Medical University; North-Eastern Federal University; Al-Farabi Kazakh National University

Aktobe, Kazakhstan

References

  1. Ахмеджанов Н. М., Небиеридзе Д. В., Сафарян А. С., Выгодин В. А., Шураев А. Ю., Ткачева О. Н., Лишута А. С. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I // Рациональная фармакотерапия в кардиологии. 2015. № 11 (3). С. 253-260
  2. Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ // Кардиоваскулярная терапия и профилактика. 2014. № 14 (4). C. 4-14
  3. Европейские рекомендации по профилактике сердечно-сосудистых заболеваний в клинической практике (Пересмотр 2016) // Российский кардиологический журнал. 2017. Т. 6 (146). С. 7-85
  4. Недогода С. В., Сабанов А. В. Достижение целевого артериального давления у пациентов с артериальной гипертензией на фоне антигипертензивной терапии в условиях реальной клинической практики // Российский кардиологический журнал. 2018. Т. 23 (11). С. 100-109
  5. Рекомендации ЕОК/ЕОА по лечению дислипидемий // Рациональная фармакотерапия в кардиологии. 2012. Прил. № 1. С. 3-63
  6. Садыкова А. Д., Смаилова А. A., Шалапов Д. М., Саттиева С. К., Ауелбекова А. А. Эпидемиология основных фатальных осложнений сердечно-сосудистых заболеваний (обзор литературы) // Медицина (Алматы). 2017. № 11 (185). С. 61-66. [In Russian]
  7. Tolpygina S. N., Polyanskaya Yu. N., Martsevich S. Yu. Hypolipidemic Therapy in Patients with Chronic Ischemic Heart Disease in 2004-2010 According to the Prognoz IBS Register. Ratsional'naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2015, 11 (2), pp. 153-158. [In Russian]
  8. Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Suboptimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019, 105 (13), pp. 975-981.
  9. Allen JK, Dennison CR. Randomized trials of nursing interventions for secondary prevention in patients with coronary artery disease and heart failure: systematic review. J Cardiovasc Nurs. 2010 May-Jun, 25 (3), pp. 207-20. DOI: 10.1097/ JCN.0b013e3181cc79be. PMID: 20386243.
  10. Aringazina A, Kuandikov T, Arkhipov V. Burden of the Cardiovascular Diseases in Central Asia. Cent Asian J Glob Health. 2018, 7 (1), p. 321.
  11. Borghi C, Tubach F, De Backer G et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe Results from the EURIKA study. Int J Cardiol. 2016, 218, pp. 83-88.
  12. Bruinooge SS, Pickard TA, Vogel W et al. Understanding the role of advanced practice providers in oncology in the United States. JAAPA. 2018, 31 (12), pp. 1-12.
  13. Chow CK, Jolly S, Rao-Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010, 121 (6), pp. 750-8.
  14. Clark H. NCDs. А challenge to sustainable human development. Lancet. 2013, 381, pp. 510-511.
  15. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. 2011, 12 (9), pp. 680-687.
  16. Altman D, Schulz KF, Moher D et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. Academia and the Profession: 17 April 2001.
  17. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013, 168 (2), pp. 934-45.
  18. Garvey C, Ortiz G. Exacerbations of chronic obstructive pulmonary disease. Open Nurs J. 2012, 6, pp. 13-19.
  19. Jayaraj JC, Davatyan K, Submanian SS Priya J. Epidemiology of Myocardial Infarction. DOI: 10.5772/ intechopen.74768.
  20. Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart. 2013, 99 (19), pp. 1421-1430.
  21. Kashkinbayeva AR, Tanbetova ZZh, Zhamaliyeva LM, Zame YA, Zhamankulova DG. Motivational interview skills teaching in the training of PHC assistants in WKMU. West Kazakhstan Medical Journal. 2020, 62 (1), pp. 25-31.
  22. Khan MAB, Hashim MJ, Mustafa H. et all. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020 Jul 23, 12 (7), e9349.
  23. Kim C, Choi I, Cho S, Kim AR, Kim W, Jee S. Do Cardiac Rehabilitation Affect Clinical Prognoses Such as Recurrence, Readmission, Revascularization, and Mortality After AMI?: Systematic Review and Meta-Analysis. Ann Rehabil Med. 2021 Feb, 45 (1), pp. 57-70.
  24. Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019, 26 (8), pp. 824-835.
  25. Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. American Heart Journal. 2011, 162 (4), pp. 571-584, e2.
  26. Management of dyslipidaemia in patients with coronary heart disease:Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019, 285, pp. 135-146.
  27. McMahon SR, Ades PA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med. 2017, 27 (6), pp. 420-425.
  28. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019, 12 (6), e005375.
  29. Piepoli MF. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Int J Behav Med. 2017 Jun, 24 (3), pp. 321-419.
  30. Pivina LM, Moldagalieva ZhT, Muzdubayeva ZhE, Belikhina TI, Markabayeva AM, Zhunussova TT. Medical and social problem of cardiovascular diseases in Kazakhstan. Science & Healthcare. 2015, 2.
  31. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017, 70 (1), pp. 1-25.
  32. Soo Hoo SY, Gallagher R, Elliott D. Predictors of cardiac rehabilitation attendance following primary percutaneous coronary intervention for ST-elevation myocardial infarction in Australia. Nurs Health Sci. 2016, 18 (2), pp. 230-7.
  33. Virani SS, Maddox TM, Chan PS et al. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015, 66 (16), pp. 1803-1812.
  34. Urbinati S, Tonet E. Cardiac rehabilitation after STEMI. Minerva Cardioangiol. 2018, 66 (4), pp. 464-470.
  35. ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018, 40 (25), p. 2092.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Zhamankulova D.G., Zhamaliyeva L.M., Kurmanalina G.L., Tanbetova Z., Grjibovski A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).